AI Article Synopsis
- The study analyzed the effectiveness and safety of factor Xa inhibitors (like apixaban, edoxaban, and rivaroxaban) and a thrombin inhibitor (dabigatran) compared to different doses of enoxaparin after orthopedic surgery.
- Statistically significant differences in venous thromboembolism (VTE) and bleeding rates were observed between the European and North American dosing regimens of enoxaparin, indicating different risk profiles.
- Overall, the factor Xa inhibitors were generally found to be more effective with lower bleeding risks compared to dabigatran at their approved doses.
Article Abstract
We carried out a dose-response model-based meta-analysis to assess venous thromboembolism (VTE) and bleeding with factor Xa (FXa) inhibitors (apixaban, edoxaban, rivaroxaban) and a thrombin inhibitor (dabigatran) compared with European (EU) (40 mg q.d.) and North American (NA) (30 mg Q12H) dose regimens of a low molecular weight heparin (enoxaparin) following orthopedic surgery. Statistically significant differences in both VTE and bleeding outcomes were found between the NA and EU doses of enoxaparin, with odds ratios (95% confidence interval) for the NA vs. EU dose of 0.73 (0.71-0.76) and 1.20 (1.14-1.29) for total VTE and major bleeding, respectively. At approved doses, estimated odds ratios vs. both doses of enoxaparin for the three FXa inhibitors (range: 0.35-0.75 for VTE; 0.76-1.09 for bleeding) compared with those for dabigatran (range: 0.66-1.21 for VTE; 1.10-1.38 for bleeding) suggested generally greater efficacy and less bleeding for the FXa inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504485 | PMC |
| http://dx.doi.org/10.1111/cts.12471 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The efficacy and safety of andexanet alfa in the treatment of anticoagulation-related major bleedings: An Italian perspective.
Thromb Res
January 2025
Neurology and Stroke Unit, AORN "Antonio Cardarelli", Naples, Italy. Electronic address:
Dependence of clot structure and fibrinolysis on apixaban and clotting activator.
Res Pract Thromb Haemost
November 2024
Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, USA.
Background: Anticoagulants prevent the formation of potentially fatal blood clots. Apixaban is a direct oral anticoagulant that inhibits factor (F)Xa, thereby impeding the conversion of prothrombin into thrombin and the formation of blood clots. Blood clots are held together by fibrin networks that must be broken down (fibrinolysis) to restore blood flow.
View Article and Find Full Text PDFImportance of individual residues in hydrophobic patch PLVIVGL (1481-1487) in FV-Short for synergistic TFPIα cofactor activity with protein S, an alanine-scanning study: AlphaFold-mediated prediction of FV-Short/TFPIα/protein S trimolecular complex structure.
J Thromb Haemost
November 2024
Department of Biochemistry and Biophysics, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Stockholm University, Solna, Sweden.
Background: In the splice variant factor (F)V-Short, 702 residues are deleted from the B domain, resulting in exposure of an acid region (AR2; 1493-1537) that binds TFPIα. FV-Short and protein S serve as synergistic TFPIα cofactors in inhibition of FXa. In the preAR2 region, a hydrophobic patch PLVIVGL (1481-1487) is crucial for synergistic TFPIα-cofactor activity and assembly of FV-Short, TFPIα, and protein S.
View Article and Find Full Text PDFCitrullination of tissue factor pathway inhibitor alpha by peptidylarginine deiminase 4 impairs its natural anticoagulant activity toward factors Xa and VIIa/tissue factor and reduces binding to its cofactor protein S.
J Thromb Haemost
November 2024
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands. Electronic address:
Article Synopsis
- - Neutrophils can release their DNA and contents to fight infections, but this can impact blood coagulation through a protein called TFPI, which is affected by an enzyme (PAD4) that alters (citrullinates) it, reducing its ability to prevent blood clotting.
- - The study aimed to explore how this citrullination affects TFPI's performance in inhibiting key components of blood coagulation, specifically FXa and the FVIIa/tissue factor complex, using various laboratory techniques.
- - Results showed that while citrullination severely weakened TFPI's ability to inhibit FXa, it still had some effect on FVIIa/tissue factor activity with the help of another protein (
Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry.
Pharmaceuticals (Basel)
October 2024
Sysmex Corporation, Kobe 651-2241, Japan.
The therapeutic effects of oral anticoagulant drugs for nonvalvular atrial fibrillation (NVAF) suggest that the three factor Xa (FXa) inhibitors may have distinct safety profiles, though this is not yet fully conclusive. This study investigated the current dosing of rivaroxaban, apixaban, and edoxaban by monitoring drug plasma concentration (PC) and coagulation activity from the viewpoint of the safety. This multicenter clinical study monitored the drug PC and two coagulation biomarkers (fibrinogen and fibrin monomer complex [FMC]) at peak and trough timing in 268 outpatients taking rivaroxaban (n = 72), apixaban (n = 71), and edoxaban (n = 125) for NVAF.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!